Japanese ministry grants orphan status to Alexion treatment

01/13/2009 | Republican-American (Waterbury, Conn.)

Japanese regulators have granted orphan-drug designation to Alexion Pharmaceuticals' Soliris, a candidate for treating a rare blood disease called paroxysmal nocturnal hemoglobinuria. Soliris will also enjoy market exclusivity for 10 years in Japan as a medication for PNH patients.

View Full Article in:

Republican-American (Waterbury, Conn.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA